Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies

mAbs

Volumn 7, Issue 1, 2015, Pages 192-198

  Duong, Minh Ngoc ^a   Matera, Eva Laure ^a   Mathé, Doriane ^a   Evesque, Anne ^a   Valsesia Wittmann, Sandrine ^a   Clémenceau, Béatrice ^b,c   Dumontet, Charles ^a,d,e  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Team 12   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

ADCC; ADCP; Ibrutinib; Idelalisib; Kinase inhibitors; Monoclonal antibodies; Obinutuzumab; Rituximab; Trastuzumab

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DACTOLISIB; IBRUTINIB; IDELALISIB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; RITUXIMAB; TRASTUZUMAB; CANCER ANTIBODY; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; IC50; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PROGRESSION FREE SURVIVAL; SCID MOUSE; TUMOR XENOGRAFT; XENOGRAFT; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICE; MICE, SCID; NEUTROPHILS; PHAGOCYTOSIS;

EID: 84921367688     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2015.989020     Document Type: Article

References (23)

1. Reichert JM. Antibodies to watch in 2014: Mid-year update. mAbs 2014; 6:799-802; PMID:24846335; http://dx.doi.org/10.4161/mabs.29282
2. Huang X, Wang S, Lee C-K, Yang X, Liu B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Lett 2011; 307:72-9; PMID:21497990; http://dx.doi.org/10.1016/j.canlet.2011.03.019
3. Gayle SS, Castellino RC, Buss MC, Nahta R. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Curr Med Chem 2013; 20:2486-99; PMID:23531216; http://dx.doi.org/10.2174/0929867311320190008
4. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang C-Y, Li Y, Li X, Chen C-T, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18:423-35; PMID:21075308; http://dx.doi.org/10.1016/j.ccr.2010.10.025
5. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123:1957-60; PMID:24652965; http://dx.doi.org/10.1182/blood-2014-01-547869
6. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013; 31:128-30; PMID:23045586; http://dx.doi.org/10.1200/JCO.2012.44.4281
7. Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117:591-4; PMID:20959606; http://dx.doi.org/10.1182/blood-2010-03-275305
8. Maira S-M, Stauffer F, Schnell C, García-Echeverría C. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009; 37:265-72; PMID:19143644; http://dx.doi.org/10.1042/BST0370265
9. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010; 24:1781-4; PMID:20703254; http://dx.doi.org/10.1038/leu.2010.154
10. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108:4178-86; PMID:16946303; http://dx.doi.org/10.1182/blood-2006-04-016907
11. Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C, Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10:178-85; PMID:21220500; http://dx.doi.org/10.1158/1535-7163.MCT-10-0385
12. Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63; PMID:18606717; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017
13. Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fournié J-J, Laurent G, Bezombes C. Rituximab inhibits B-cell receptor signaling. Blood 2010; 115:985-94; PMID:19965664; http://dx.doi.org/10.1182/blood-2009-08-237537
14. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369:507-16; PMID:23782157; http://dx.doi.org/10.1056/NEJMoa1306220
15. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369:32-42; PMID:23782158; http://dx.doi.org/10.1056/NEJMoa1215637
16. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371:213-23; PMID:24881631; http://dx.doi.org/10.1056/NEJMoa1400376
17. Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A. The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol Lond Engl 2014; 1-9; PMID:24901734; http://dx.doi.org/10.2217/fon.14.119
18. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370:997-1007; PMID:24450857; http://dx.doi.org/10.1056/NEJMoa1315226
19. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88-94; PMID:23045577; http://dx.doi.org/10.1200/JCO.2012.42.7906
20. Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13:R115; PMID:21752263; http://dx.doi.org/10.1186/ar3400
21. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9:5866-73; PMID:14676108
22. Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouillé V, Quittet P, Klein B, Rossi J-F. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008; 26:2725-31; PMID:18427151; http://dx.doi.org/10.1200/JCO.2007.13.7729
23. Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood 2006; 107:4669-77; PMID:16514054; http://dx.doi.org/10.1182/blood-2005-09-3775